Show simple item record

dc.contributor.authorLarkin, Emmet P.
dc.contributor.authorShubsachs, Alexander P. W.
dc.date.accessioned2017-09-20T15:57:49Z
dc.date.available2017-09-20T15:57:49Z
dc.date.issued1991
dc.identifier.citationCollins, P. J., Larkin, E. P. & Shubsachs, A. P. W. (1991). Lithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatrica Scandinavica, 84 (2), pp.150-154.
dc.identifier.other10.1111/j.1600-0447.1991.tb03119.x
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9887
dc.description.abstractThe value of lithium carbonate as an adjunctive treatment of resistant schizophrenia was tested in a 4‐week clinical trial using a single‐blind, randomized, consent design. Treatment and control groups were drawn from a population of detained patients in an English special (maximum security) hospital. The 2 groups were comparable in terms of age, sex, severity of symptoms, length of hospitalization and concurrent neuroleptic dosage. The addition of lithium carbonate to the treatment regimen did not result in symptomatic improvement in patients completing the treatment protocol. The ethical and practical difficulties raised by the trial are discussed. Copyright © 1991, Wiley Blackwell. All rights reserved
dc.description.urihttp://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.1991.tb03119.x/full
dc.subjectSchizophrenia
dc.subjectDrug therapy
dc.titleLithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients
dc.typeArticle
html.description.abstractThe value of lithium carbonate as an adjunctive treatment of resistant schizophrenia was tested in a 4‐week clinical trial using a single‐blind, randomized, consent design. Treatment and control groups were drawn from a population of detained patients in an English special (maximum security) hospital. The 2 groups were comparable in terms of age, sex, severity of symptoms, length of hospitalization and concurrent neuroleptic dosage. The addition of lithium carbonate to the treatment regimen did not result in symptomatic improvement in patients completing the treatment protocol. The ethical and practical difficulties raised by the trial are discussed. Copyright © 1991, Wiley Blackwell. All rights reserved


This item appears in the following Collection(s)

Show simple item record